Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Date:3/22/2011

ered related to Cinryze and none led to discontinuation of treatment;
  • In the open-label treatment study in which 87 laryngeal attacks occurred in 37 subjects:
    • Median time to beginning of relief of the first treated laryngeal attacks was 60 minutes, comparable to the overall median response time for attacks at all anatomic locations (45 minutes);
    • In subjects treated for more than one laryngeal attack, the effect of Cinryze was not reduced with subsequent repeated administration; median time to beginning of relief for the second and third laryngeal attacks were 30 and 38 minutes, respectively.

  • About Cinryze® (C1 esterase inhibitor [human])

    Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by U.S. FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency.

    Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials.

    Cinryze is for intr
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
    2. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
    3. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
    4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
    5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
    6. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
    7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
    8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
    9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
    10. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
    11. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... , August 3, 2015 ... announced today that it has acquired ... Inc. for $300 million. With the acquisition, Shire ... drops combining 0.6% povidone iodine (PVP-I) and 0.1% ... treatment of infectious conjunctivitis, an ocular surface condition ...
    (Date:8/2/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... to discover and develop antisense therapies for cardiovascular, ... on a broad existing relationship between the two ... therapeutic areas using novel RNA-targeted treatments. It also ... antisense technology to diseases of the kidney. ...
    (Date:8/2/2015)... Texas , Aug. 3, 2015  Lexicon ... that the pivotal TELESTAR Phase 3 clinical trial ... oral telotristat etiprate in treating cancer patients with ... the current standard of care. Telotristat etiprate was ... Prize-winning technology, and is the company,s first discovery ...
    Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
    ... 7, 2010 Where do you start when trying to ... ), an independent nonprofit that researches the best approaches to ... release of its 5th annual list of Top 10 ... free download with registration, the list features the ...
    ... Research Group (MRG), the global authority on medical technology ... the US clot management device market.   ... report provides important insight into the device-based treatments ... of medical device manufacturers in this field. The report ...
    Cached Medicine Technology:ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 2ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 3Millennium Research Group to Release Their Latest US Clot Management Data 2
    (Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
    (Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Kill Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can ... back pain in patients. According to the report, the new study showed that harvesting ...
    (Date:8/3/2015)... , ... August 03, 2015 , ... Illinois Health & ... July 31. , The acquisition includes all of IBAM NA’s cyclotron sites and ... have both, a robust regionally located business, as well as a large manufacturing hub ...
    (Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health ... overall performance of the company’s Medicare and Federal Employee Programs (FEP) lines of ... deliver better health for members. In this role, Scott is responsible for overseeing ...
    Breaking Medicine News(10 mins):Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
    ... (30), a,quadriplegic patient who is dependent on a respirator since ... LASIK procedure performed,by Drs. Jeffrey and Joseph Dello Russo. Eric ... his neck and severing his spinal cord. Since,that day, he ... his body below his upper neck down and is able ...
    ... Names Kaiser Permanente "Highest in,Member Satisfaction" Among All ... Kaiser Permanente Colorado is the,top-ranked commercial health plan ... a joint ranking by U.S. News & World ... To view the Multimedia News Release, go ...
    ... survival rates , , FRIDAY, Nov. 7 (HealthDay News) -- ... adults requiring surgery to repair a congenital heart defect, ... occurs when there,s abnormal pre-birth development of the heart ... analyzed a national database to identify 30,250 congenital heart ...
    ... October 31, 2008 -- Children under the age of three ... behavioral or developmental problems later compared to children who had ... at Columbia University Mailman School of Public Health and the ... children who were born into the New York State Medicaid ...
    ... Will Be Celebrity Host of Show at Nassau Coliseum, ... today,announced the first of its 2009 Concert Series -- a ... Cancer Research,Foundation., The show will be held on February ... go on sale Monday, November 10th at 10am,through Ticketmaster.com or ...
    ... National Health Science Summit, DALLAS, Nov. 7 ... today announced Dr. Valentin Fuster, director of,Mount Sinai ... Prize.,The Prize was presented to Dr. Fuster by ... Health Science Summit held on,November 7, 2008 in ...
    Cached Medicine News:Health News:Historic LASIK Surgery Performed on Quadriplegic Patient to Preserve his Communication Abilities 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 3Health News:Pediatric Heart Surgeons May Be Best Choice for Adults 2Health News:General anesthesia for hernia surgery in children and risk of later developmental problems 2Health News:Barry Manilow Brings Valentine's and Music to New York With Concert to Raise Funds for Breast Cancer Research 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 3
    A patient skin prepping solution in a self-contained applicator combining two proven broad-spectrum antimicrobials: alcohol for fast kill and fast drying (3 minutes on skin), and an iodophor for pers...
    These are simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in healthcare facilities....
    Pre-Saturated Sponge Sticks...
    ... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
    Medicine Products: